News articles |


Back to All Articles

Shore Capital Announces Formation of Southern Ear, Nose, Throat, and Allergy Physicians

May 17, 2019

May 17, 2019 ‐ Shore Capital Partners (“Shore Capital” or “Shore”) is pleased to announce that it has formed Southern Ear, Nose, Throat and Allergy Physicians (“SENTA”) and completed a strategic partnership with Northwest ENT and Allergy Center (“Northwest ENT” or the “Company”). Northwest ENT is a leading ear, nose and throat (“ENT”) and allergy services provider with seven locations including two affiliated ambulatory surgery centers in the Greater Atlanta, Georgia metro area. The Company offers comprehensive medical and surgical ENT and allergy services, including treatment for thyroid disorders, sinus conditions, ear pain, allergies, and throat disorders. Northwest ENT will continue to operate under its brand.

Shore Capital is partnering with Northwest ENT’s existing four partner physicians, Dr. Drew Locandro, Dr. Shatul Parikh, Dr. Ryan Kauffman and Dr. Avani Ingley, who have established a reputation for high quality medical and surgical specialty ENT and allergy care and lead a team of six doctors, one physician’s assistant, five audiologists and one nurse practitioner. Drew, Shatul, Ryan and Avani, and the Northwest ENT team have demonstrated impressive growth through the addition of new service lines and capabilities, recruiting talented physicians and specialists, and new center openings. “We are proud of the clinical foundation we have built as a team and are excited to continue to expand patient and referral partner access to our treatment and surgical services through a new phase of transformational growth. Our partnership with Shore Capital will allow us to accelerate our organic growth including opening new locations, hiring additional providers, and expanding our patient care and business support services while simultaneously pursuing affiliations with other leading practices,” said Dr. Parikh.

Shore plans to invest in infrastructure to further standardize operations and offer finance, accounting, compliance, marketing, human resources, IT and other support services to allow clinicians to focus on providing high quality ENT and allergy services. “Shore Capital is the ideal partner to help further our medical mission across a broader geographic reach and shares our commitment to leading clinical quality, operational excellence and increased patient access,” said Dr. Locandro. “I have high aspirations for what we can collectively accomplish and offer to our patients and their referring doctors,” commented Dr. Ingley. “We are thrilled about the partnership with Shore Capital and the deep healthcare experience and dedicated management and support services they bring to the table.”

SENTA and Northwest ENT will pursue affiliations with independent ear, nose and throat and stand alone allergy practices across the Southeast in order to build a leading network of doctors that maintains a patient-first culture with a clear focus on clinical care. “The partnership provides us with access to capital, administrative resources, operating expertise and strategic guidance while maintaining absolute focus on clinical quality as we seek to execute on our vision of building a leading ENT and allergy practice in the Southeast,” added Dr. Kauffman.

“We could not be more excited to partner with the entire Northwest ENT team and look forward to creating a leading ENT and allergy provider in the Southeast, while offering the highest level of support to our practices and clinicians,” said Chris Mioton, Chairman of SENTA. “Northwest ENT provides a solid foundation to build a best-in-class organization as SENTA seeks to be the partner of choice for practices throughout the Southeast who provide high quality patient care and desire a strategic partner to support their business operations and accelerate growth.”

This investment represents the eighth platform investment out of Shore Capital Partners Fund II, L.P., a $190 million investment vehicle raised in April 2017.

Shore Capital Announces Closing of HC Fund III and F&B Fund I

May 14, 2019

April 17, 2019 ‐ Shore Capital Partners (“Shore” or the “Firm”), a strategic private equity firm focused on the healthcare and food & beverage industries, announced the first and only closings of its third institutional healthcare private equity fund, Shore Capital Healthcare Partners Fund III (“HC Fund III”), and its inaugural food & beverage fund, Shore Capital Food & Beverage Partners Fund I (“F&B Fund I”). HC Fund III raised $293 million, while F&B Fund I raised $148 million. With these respective closings, Shore now manages a total committed capital base of more than $1 billion.

HC Fund III surpassed its original target of $250 million and was substantially oversubscribed. HC Fund III will continue the successful investment strategy employed by the firm’s partners Justin Ishbia, Ryan Kelley, Michael Cooper, John Hennegan, Don Pierce and Chris Mioton. HC Fund III will invest primarily in control buyouts, focusing on microcap healthcare businesses with revenues between $5 million and $100 million.

F&B Fund I, Shore’s newly established vehicle led by Justin Ishbia and Richard Boos, surpassed its original target of $125 million and was substantially oversubscribed. F&B Fund I will aim to make control equity investments in food & beverage manufacturing, distribution, packaging, and related B2B service companies that have between $5 million and $100 million of revenue.

Commitments to both HC Fund III and F&B Fund I came from the firm’s existing investors, plus select new limited partners. Together, the funds attracted strong interest from many sophisticated institutions in North America, resulting in a diverse investor base comprised of leading university endowments, financial institutions, funds of funds and family offices. Additionally, the partners of Shore have committed to invest a substantial amount of capital alongside both funds.

“We are thrilled and humbled by the reception these funds have received from such a highly-respected group of investors,” said Justin Ishbia, Founder and Managing Partner of Shore Capital Partners. “Having the ability to expand our expertise and knowledge into the food and beverage space while simultaneously continuing our original healthcare-focused strategy is an attractive opportunity for our limited partners and firm as whole. As we strive to continue achieving a top-tier track record, we sincerely thank our limited partners who have instilled a significant amount of trust and confidence in our experienced and talented team of investment and operating professionals.”

“In addition to our third healthcare-focused fund, we are very pleased to have successfully closed our inaugural food and beverage fund and look forward to partnering with entrepreneurs and seasoned executives to drive impactful growth,” said Ishbia. “As has been the case for many years and various cycles, we are confident that the food and beverage industry will continue to present quality investment opportunities, particularly within a number of niche sectors. We are eager to begin deploying this capital to help companies reach their full potential.”

Kirkland & Ellis LLP served as legal advisor to Shore Capital Partners for the fundraising efforts. Shore did not use a placement agent.

Ready to connect with Shore?